1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece.
Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.
Curr Med Chem. 2019;26(5):837-854. doi: 10.2174/0929867324666170727103357.
During the last few years, a significant number of studies have attempted to clarify the underlying mechanisms that lead to the presentation of atrial fibrillation (AF). Inflammation is a key component of the pathophysiological processes that lead to the development of AF; the amplification of inflammatory pathways triggers AF, and, in tandem, AF increases the inflammatory state. Indeed, the plasma levels of several inflammatory biomarkers are elevated in patients with AF. In addition, the levels of specific inflammatory biomarkers may provide information regarding to the AF duration. Several small studies have assessed the role of anti-inflammatory treatment in atrial fibrillation but the results have been contradictory. Large-scale studies are needed to evaluate the role of inflammation in AF and whether anti-inflammatory medications should be routinely administered to patients with AF.
在过去的几年中，大量研究试图阐明导致心房颤动（AF）发生的潜在机制。炎症是导致 AF 发生的病理生理过程的关键组成部分；炎症途径的放大引发 AF，而 AF 则同时增加炎症状态。事实上，患有 AF 的患者的几种炎症生物标志物的血浆水平升高。此外，特定炎症生物标志物的水平可能提供有关 AF 持续时间的信息。几项小型研究评估了抗炎治疗在心房颤动中的作用，但结果相互矛盾。需要进行大规模研究来评估炎症在 AF 中的作用以及抗炎药物是否应常规用于 AF 患者。
